MEETING OF PHARMACISTS SPECIALIZING IN NEPHROLOGY IN QUEBEC
Friday, October 4, 2024 (morning sessions)
from 9:00 to 12:00
Room 201
*** NO SIMULTANEOUS TRANSLATION WILL BE AVAILABLE ***
09:00 - 9:30 | ARRIVAL OF PARTICIPANTS (REGISTRATION) | Foyer 200 |
PLENARY SESSIONS | Room 201 | |
09:30 - 9:40 | OPENING REMARKS | Room 201 |
Conference 1 9:40 - 10:30 | “GOUT AND CKD: WHAT TO DO? HOW TO DO IT? WHEN TO DO IT?” (Lecture in French) | Ms. Marjolaine Giroux |
10:30 - 10:40 | Question Period | |
10:40 - 10:55 | HEALTH | Foyer 200 |
Conference 2 10:55 - 11:45 | “ALTERED DRUG DISPOSITION IN KIDNEY DISEASE: THE ROLE OF NONRENAL ELIMINATION” | Dr. Thomas D. Nolin |
11:45 - 11:55 | Question Period | |
11:55 - 12:00 | CLOSING WORDS | |
12:00 | LUNCH | Room 200 |
This program receives unrestricted educational grants from pharmaceutical companies Amgen Canada and Novo Nordisk without any regards to the choice of speakers, topics, choice of members of the scientific committee. We also offer our thanks to Amgen Canada as exhibitor.
CONFERENCE 1
“GOUT AND CKD: WHAT TO DO? HOW TO DO IT? WHEN TO DO IT?” (Lecture in French)
SPEAKER
Ms. Marjolaine Giroux, Pharm. D., M.Sc
LEARNING OBJECTIVES
- To discuss the pathogenesis and prevalence of gout, in the presence of chronic kidney disease.
- To describe the impact of gout and its deleterious consequences for the CKD clientele.
- To select an appropriate therapeutic strategy for the treatment for acute manifestations of gout.
- To integrate a useful preventive plan for the care of CKD patients suffering from gout.
- To explore controversial aspects of the management of gout in this context.
CONFERENCE 2
“ALTERED DRUG DISPOSITION IN KIDNEY DISEASE: THE ROLE OF NONRENAL ELIMINATION”
SPEAKER
Dr. Thomas D. Nolin, Pharm. D., PhD., FCCP, FCP, FASN
LEARNING OBJECTIVES
- To analyze the impact of CKD on the metabolism and elimination of drug therapies, in relation to renal and non renal clearance.
- To discuss clinical and or experimental data on this topic.
- To explore recommendations of FDA and Health Canada to pharmaceutical companies regarding their elaboration of drug monographs, more specifically in the presence of CKD.
22nd ANNUAL CONFERENCE OF “FONDATION D.E.V.E.N.I.R.”
Organized in collaboration with the SQN
Friday, October 4th, and Saturday, October 5th, 2024
Démarches Visant à enrayer l’Émergence des conséquences Néfastes de l’Insuffisance Rénale
Skills development in the CanMEDS roles targeted by this activity:
- Medical Expert
- Communicator
- Collaborator
- Leader
- Scholar
- Professional
Accreditation
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and a Recognized Professional Development Activity (Category A) as defined by the Collège des médecins du Québec. This activity was approved by the direction de Développement professionnel continu (DDPC) of the Fédération des médecins spécialistes du Québec.
You may claim a maximum of 8.5 Accredited Group Learning Activity (Section 1) / Recognized Professional Development Activity (Category A) hours. Participants must claim a number of hours consistent with their attendance.
GENERAL LEARNING OBJECTIVES
- To promote, through multidisciplinarity, a comprehensive healthcare approach for clients with chronic kidney disease and for related co-morbid clinical conditions.
- To generate optimal use of the skills of the members of the multidisciplinary teams (physicians, pharmacists, nurses, dietitians), in the healthcare process for this client group.
*** NOTE: For the 22ND ANNUAL CONFERENCE OF “FONDATION D.E.V.E.N.I.R.”, participants can register and join either the half-day session of this continuing medical education on October 4th or the half-day session on Saturday, October 5th, or opt for both half-day sessions. ***
The specific objectives for each conference are indicated at the end of the program (see below)
SCIENTIFIC PROGRAM – DAY 1
***Note: A simultaneous translation service from English to French and from French to English will be available. You must bring your headphones and your electronic devices for accessing the translation service.
Friday, October 4, 2024
11:30-13:00 | ARRIVAL OF PARTICIPANTS (Registration) | Foyer 200 |
PLENARY SESSIONS | Room 201 | |
13:00-13:15 | OPENING REMARKS | Dr. Daniel Garceau Dr. Louis-Denis Poulin |
Conference 1 13:15-14:15 | “ARTIFICIAL INTELLIGENCE IN NEPHROLOGY: FOR NOW, OR FOR LATER?” | Dr. Wisit Cheungpasitporn |
Conference 2 14:15-15:15 | “AUTOIMMUNE DISEASES, VASCULITIS AND PREGNANCY; HOW TO TRANSFORM A DREAM TO REALITY!” | Prof. Angela Tincani |
15:15-15:50 | HEALTH BREAK | Foyer 200 |
Conference 3 15:50-17:55 | “HIGHLIGHTS IN 2024 TO SHARE” (Lectures in French) | |
15:50-16:15 : The Nurse’s / SNP’s Vision | Ms. Isabelle Vaillant | |
16:15-16:40 : The Pharmacist’s Vision | Ms. Jodianne Couture | |
16:40-17:05 : The Nephrologist’s Vision | Dr. Philippe Lachance | |
17:05-17:30 The Nutritionist’s Vision | Ms. Roxanne Papineau | |
17:30-17:55 : Question Period | ||
18:30-19:30 | COCKTAIL | Foyer 200 |
19:30-22:00 | DINNER | Room 201 |
This program receives unrestricted educational grants from pharmaceutical companies Amgen Canada and Otsuka Canada without any regards to the choice of speakers, topics, choice of members of the scientific committee. We also offer our thanks to Amgen Canada as exhibitor.
SCIENTIFIC PROGRAM – DAY 2
Note: A simultaneous translation service from English to French and from French to English will be available. You must bring your headphones and your electronic devices for accessing the translation service.***
Saturday, October 5, 2024
7:00-8:00 |
BUFFET BREAKFAST |
Foyer 200 |
PLENARY SESSIONS |
Room 201 | |
8:00-8:10 |
OPENING REMARKS |
Dr. Daniel Garceau Dr. Louis-Denis Poulin |
Conference 4 8:10-9:10 |
“WATER AND SALT INTAKE WITH CKD; IS IT TOO MUCH OR NOT ENOUGH?” ” | Dr. Biff F. Palmer |
Conference 5 9:10-10:25 |
“A KIDNEY GRAFT RECIPIENT; THE BEGINNING AND THE END OF THE STORY” | |
Part 1: 9:10-9:40 |
“PREEMPTIVE KIDNEY GRAFT: A USER GUIDE” | Dr. Michelle A. Josephson |
Part 2: 9:40-10:10 |
“THE FAILING KIDNEY GRAFT; ANOTHER USER GUIDE FOR HEALTHCARE PROFESSIONALS INVOLVED IN CKD CARE” | Dr. Michelle A. Josephson |
10:10-10:25 | JOINT Q&A AND DISCUSSION SESSION | |
10:25-11:00 |
HEALTH BREAK |
Foyer 200 |
Conference 6 11:00-12:25 |
“SHARED DECISION MAKING IN CKD; A PATIENT’S AND A CAREGIVER’S PERSPECTIVE” | |
Part 1: 11:00-11:30 |
“SHARED DECISION MAKING: WHAT IS THE LITERATURE AND RESEARCH TELLING US IN 2024?” (Lecture in French) |
Dr. Patrick Archambault |
Part 2: 11:30-11:55 |
“SHARED DECISION MAKING IN CKD; A PATIENT’S PERSPECTIVE” (Lecture in French) |
Mr. Réjean Lemoine |
11:55-12:25 | JOINT Q&A AND DISCUSSION SESSION | |
12:25-12:35 |
CLOSING WORDS |
Dr. Daniel Garceau Dr. Louis-Denis Poulin |
12:35-13:45 |
BUFFET LUNCH |
Room 200 |
This program receives unrestricted educational grants from pharmaceutical companies Amgen Canada and Otsuka Canada without any regards to the choice of speakers, topics, choice of members of the scientific committee. We also offer our thanks to Amgen Canada as exhibitor.
OBJECTIVES
CONFERENCE 1
“ARTIFICIAL INTELLIGENCE IN NEPHROLOGY: FOR NOW, OR FOR LATER?”
SPEAKER
Dr. Wisit Cheungpasitporn, MD, FACP, FASN, FAST
TARGETED CANMEDS SKILLS: | ☐ Medical Expert | ☐ Communicator | ☐ Collaborator | ☒ Leader |
☐ Health Advocate | ☒ Scholar | ☐ Professional |
LEARNING OBJECTIVES
- To briefly discuss the concepts and the broad current usage of machine learning, artificial intelligence and natural language processing.
- To discuss the potential usage of artificial intelligence in the field of clinical nephrology, using specifical examples, in relation to:
- diagnosis of diseases
- prediction of outcomes
- selection of treatments.
- To explore the potential benefits and limitations of usage of artificial intelligence in this context.
- To describe the usage of these tools in the next 5 to 10 years for healthcare providers involved in nephrology care.
CONFERENCE 2
“AUTOIMMUNE DISEASES, VASCULITIS AND PREGNANCY; HOW TO TRANSFORM A DREAM TO REALITY!”
SPEAKER
Prof. Angela Tincani, MD
TARGETED CANMEDS SKILLS: | ☒ Medical Expert | ☐ Communicator | ☐ Collaborator | ☐ Leader |
☐ Health Advocate | ☒ Scholar | ☐ Professional |
LEARNING OBJECTIVES
Using clinical cases for a multidisciplinary audience (nephrologists, pharmacists, nurses, dietitians):
- To discuss the impact of some current autoimmune diseases and vasculitis (lupus, ANCA vasculitis) on fertility for young women afflicted by these diseases.
- To review the clinical management before and during pregnancy of these women, more specifically in relation to:
- usage of immunosuppressive drugs
- monitoring of diseases activity
- impact of these diseases on blood pressure control and kidney function
- To recognize, prevent or manage specific complications related to these diseases during pregnancy, such as:
- thromboembolic disorders
- preeclampsia
- antiphospholipid syndrome
- flare-up of these diseases
- To schematize the impact of these diseases and their therapeutics on lactation and future baby’s health.
CONFERENCE 3
“HIGHLIGHTS IN 2024 TO SHARE” (Lectures in French)
SPEAKERS
Ms. Isabelle Vaillant, M.Sc Inf.
Ms. Jodianne Couture, B. Pharm., M.Sc
Dr. Philippe Lachance, MD, M.Sc
Ms. Roxanne Papineau, Dt.P
TARGETED CANMEDS SKILLS: | ☒ Medical Expert | ☒ Communicator | ☒ Collaborator | ☐ Leader |
☐ Health Advocate | ☒ Scholar | ☐ Professional |
LEARNING OBJECTIVES
To share with colleagues the vision of one member of each professional group involved, and more specifically:
- To present relevant concepts (diagnostic, therapeutic, behavioural, organizational approaches or notions acquired in 2024) to the members of multidisciplinary teams in nephrology.
- To illustrate how the concepts of interest acquired in 2024 can apply in a multidisciplinary practice for the different groups of healthcare professionals.
- To integrate the concepts conveyed in the presentation to the current practice of the members of the healthcare teams.
CONFERENCE 4
“WATER AND SALT INTAKE WITH CKD; IS IT TOO MUCH OR NOT ENOUGH?”
SPEAKER
Dr. Biff F. Palmer, MD
TARGETED CANMEDS SKILLS: | ☐ Medical Expert | ☐ Communicator | ☒ Collaborator | ☐ Leader |
☐ Health Advocate | ☒ Scholar | ☐ Professional |
LEARNING OBJECTIVES
Using clinical cases or vignettes in this conference for a multidisciplinary audience (pharmacists, nurses, dietitians, nephrologists)
- To discuss the rationale of fluid and salt intake targets in the presence of CKD stage 3 to 5.
- To describe clinical tools available in current practice to better define target weight and optimal fluid balance for this clientele, and to prevent overhydration or dehydration.
- To explore in this context ways to correct or prevent hypo or hypernatremic states and to predict the need of water or salt intake.
- To promote future usage of readily clinical tools to better advice stage 3 to 5 CKD patients on their daily fluid and salt intake.
CONFERENCE 5
“A KIDNEY GRAFT RECIPIENT; THE BEGINNING AND THE END OF THE STORY”
TARGETED CANMEDS SKILLS: | ☒ Medical Expert | ☐ Communicator | ☐ Collaborator | ☐ Leader |
☐ Health Advocate | ☒ Scholar | ☐ Professional |
Part 1: “PREEMPTIVE KIDNEY GRAFT: A USER GUIDE”
SPEAKER
Dr. Michelle A. Josephson, MD
LEARNING OBJECTIVES
- To demonstrate the benefits of pre-emptive kidney grafts over dialysis therapies for eligible CKD patients.
- To describe selection and exclusion criteria to better define the CKD clientele eligible for pre-emptive kidney graft.
- To discuss the potential benefits and hazards related to pre-emptive kidney graft, in relation to:
- age of the recipients
- residual value of eGFR
- etiologies of kidney failure
- other pertinent aspects
Part 2: “A KIDNEY GRAFT RECIPIENT; THE BEGINNING AND THE END OF THE STORY”
SPEAKER
Dr. Michelle A. Josephson, MD
LEARNING OBJECTIVES
- To briefly discuss the kidney graft survival time, and the major causes of a failing graft or major eGFR drop.
- To propose strategies for clinicians involved in the care of these patients, in the model of pre-dialysis clinics in relation to:
- management of immunosuppressive drugs
- preservation on residual eGFR
- removal (or not) of the failing kidney graft
- To analyze the benefits related to a new pre-emptive kidney transplantation versus the beginning of dialysis therapies.
CONFERENCE 6
“SHARED DECISION MAKING IN CKD; A PATIENT’S AND A CAREGIVER’S PERSPECTIVE”
TARGETED CANMEDS SKILLS: | ☒ Medical Expert | ☒ Communicator | ☒ Collaborator | ☐ Leader |
☐ Health Advocate | ☐ Scholar | ☒ Professional |
Part 1: “SHARED DECISION MAKING: WHAT IS THE LITERATURE TELLING US IN 2024?” (Lecture in French)
SPEAKER
Dr. Patrick Archambault, MD, M.Sc, FRCPC
LEARNING OBJECTIVES
- To briefly define the concept of shared decision making in 2024.
- To explore the challenges to achieve an adequate process of shared decision, in relation to the patient’s background knowledge of his disease:
- quality and clarity of explanations
- resolution of matters raised
- mixed messaging
- interaction with the patient’s family members and other caregivers
- To provide helpful clues and tools to achieve better communication and shared decision process.
- To demonstrate during the joint discussion period, with a moderator and a patient suffering from CKD, the potential usage of these tools.
(***Following this conference, a patient will discuss his personal experience of decision-making process, in relation to his status of CKD patient, in different aspects of his medical history: end-stage kidney failure, choice of dialysis modality, possibility of future kidney transplant).
Part 2: “SHARED DECISION MAKING: A PATIENT’S PERSPECTIVE.” (Lecture in French)
SPEAKER
Mr. Réjean Lemoine
LEARNING OBJECTIVES
- To describe the journey of a CKD patient, from a personal perspective, from CKD stage 3 to 5 to dialysis, and eventually to a kidney transplant.
- To demonstrate with specific and personal examples the impact of the decision-making process on:
- acceptance of his disease
- integration of his own values and priorities in the decision-making process
- emotions
- To summarize some aspects to achieve a better quality of shared decision-making process.
- To discuss during the joint session with the moderator and the first speaker ways to enhance in the future the quality of this process.
11th F.E.N. (FORUM ÉDUCATIONNEL POUR LES NÉPHROLOGUES, SECTION QUÉBEC)
Organized in collaboration with the SQN
Saturday, October 5th, and Sunday, October 6th, 2024
Skills development in the CanMEDS roles targeted by this activity:
- Medical Expert
- Collaborator
- Leader
- Health Advocate
- Scholar
- Professional
Accreditation
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and a Recognized Professional Development Activity (Category A) as defined by the Collège des médecins du Québec. This activity was approved by the direction de Développement professionnel continu (DDPC) of the Fédération des médecins
spécialistes du Québec.
You may claim a maximum of 7.5 Accredited Group Learning Activity (Section 1) / Recognized Professional Development Activity (Category A) hours. Participants must claim a number of hours consistent with their attendance.
GENERAL LEARNING OBJECTIVES
- To explore new useful diagnostic or therapeutic avenues in 2024.
- To promote professional exchanges in discussion forums.
- To address new cutting-edge scientific concepts, through interviews with national or international content experts.
- To optimize the quality of healthcare to be provided to clients with nephrology-related clinical conditions.
***NOTE: F.E.N. 2024 is a full-day CME activity. Unlike the 22ND ANNUAL CONFERENCE OF “FONDATION D.E.V.E.N.I.R.”, participants will only be able to register and attend the entire educational program F.E.N.***
SCIENTIFIC PROGRAM – DAY 1
***Note: NO SIMULTANEOUS TRANSLATION WILL BE AVAILABLE***
Saturday, October 5, 2024
11:30-13:45 | ARRIVAL OF PARTICIPANTS | Foyer 200 |
PLENARY SESSIONS | Room 201 | |
13:45-13:55 | OPENING REMARKS | Dr. Daniel Garceau |
Conference 1 13:55-15:05 | “LUPUS NEPHRITIS: WHAT’S NEW IN 2024?” | Dr. Brad Rovin |
Conference 2 15:05-16:15 | “CYSTIC KIDNEY DISEASES: WHAT ELSE OTHER THAN POLYCYSTIC KIDNEY DISEASE?” | Dr. Johannes Münch |
16:15-16:45 | HEALTH BREAK | Foyer 200 |
Conference 3 16:45-17:55 | “RESISTANT HYPERTENSION: WHAT WE SHOULD KNOW AND DO NEXT AS NEPHROLOGISTS?” | Dr. Debbie L. Cohen |
18:00-19:30 | COCKTAIL | Foyer 200 |
19:30- 22:00 | DINNER | Room 201 |
This program receives unrestricted educational grant from pharmaceutical company Amgen Canada, without any regards to the choice of speakers, topics, choice of members of the scientific committee. We offer our thanks to Amgen Canada as exhibitor.
SCIENTIFIC PROGRAM – DAY 2
***Note: NO SIMULTANEOUS TRANSLATION WILL BE AVAILABLE***
Sunday, October 6, 2024
7:00-8:00 | BUFFET BREAKFAST> | Room 200 |
PLENARY SESSIONS | Room 201 | |
8:00-8:10 | OPENING REMARKS | Dr. Daniel Garceau |
Conference 4 8:10-9:20 | “FOCAL SEGMENTAL GLOMERULOSCLEROSIS: SHADOWS AND LIGHT” | Dr. Sanjeev Sethi |
Conference 5 9:20-10:30 | “MANAGEMENT OF HYPONATREMIA: MYTHS AND REALITIES” | Dr. Biff F. Palmer |
10:30-11:00 | HEALTH BREAK | Foyer 200 |
Conference 6 11:00-12:10 | “FLUID MANAGEMENT IN THE INTENSIVE CARE UNIT: TOO MUCH, TOO LITTLE, OR JUST ENOUGH?” (Lecture in French) | Dr. William Beaubien-Souligny |
12:10-12:20 | CLOSING WORDS | Dr. Daniel Garceau |
12:20-13:30 | BUFFET LUNCH | Room 200 |
This program receives unrestricted educational grant from pharmaceutical company Amgen Canada, without any regards to the choice of speakers, topics, choice of members of the scientific committee. We offer our thanks to Amgen Canada as exhibitor.
OBJECTIVES
CONFERENCE 1
“LUPUS NEPHRITIS: WHAT’S NEW IN 2024?”
SPEAKER
Dr. Brad Rovin, MD, FASN, FACP
TARGETED CANMEDS SKILLS: | ☒ Medical Expert | ☐ Communicator | ☐ Collaborator | ☐ Leader |
☐ Health Advocate | ☒ Scholar | ☐ Professional |
LEARNING OBJECTIVES
- To discuss the latest updates of KDIGO and EULAR guidelines regarding the management of lupus nephritis, in relation to induction and remission treatments.
- To explore the benefits of usage of multiple different therapies (such as belimumab and voclosporin) to treat patients afflicted by lupus nephritis.
- To schematize an algorithm of therapies and follow-up tests (blood tests, kidney biopsies) to optimize the management of these patients.
- To suggest therapeutic approaches in the presence of refractory disease.
CONFERENCE 2
“CYSTIC KIDNEY DISEASES: WHAT ELSE OTHER THAN POLYCYSTIC KIDNEY DISEASE?”
SPEAKER
Dr. Johannes Münch, MD
TARGETED CANMEDS SKILLS: | ☒ Medical Expert | ☐ Communicator | ☐ Collaborator | ☐ Leader |
☐ Health Advocate | ☒ Scholar | ☐ Professional |
LEARNING OBJECTIVES
Using clinical cases
- To explore the spectrum of ciliopathies and monogenic cystic renal diseases, notwithstanding polycystic kidney diseases.
- To discuss the clinical presentation of some of these ciliopathies (nephronophthisis, Bardet-Biedl syndrome, Joubert syndrome, ciliopathies with extra-renal manifestations), ARPKD, Meckel-Gruber syndrome, tuberous sclerosis complex, or other diseases.
- To integrate usage of genetic testing, if appropriate, to optimize the diagnosis and the management of these diseases.
- To propose useful clinical tools to help healthcare professionals to detect and diagnose these diseases.
CONFERENCE 3
“RESISTANT HYPERTENSION: WHAT WE SHOULD KNOW AND DO NEXT AS NEPHROLOGISTS?”
SPEAKER
Dr. Debbie L. Cohen, MD
TARGETED CANMEDS SKILLS: | ☒ Medical Expert | ☐ Communicator | ☐ Collaborator | ☐ Leader |
☒ Health Advocate | ☒ Scholar | ☐ Professional |
LEARNING OBJECTIVES
- To recognize the problem of resistant hypertension, to discuss its major etiologies and its prevalence in reference centers.
- To explore methods to better assess patients suffering from resistant hypertension, and to integrate useful diagnostic tools to better manage these patients.
- To debate the benefits and limitations of renal denervation in this context.
- To schematize useful diagnostic and therapeutic approaches for nephrologists involved in the care of these patients.
CONFERENCE 4
“FOCAL SEGMENTAL GLOMERULOSCLEROSIS: SHADOWS AND LIGHT”
SPEAKER
Dr. Sanjeev Sethi, MD, PhD
TARGETED CANMEDS SKILLS: | ☒ Medical Expert | ☐ Communicator | ☐ Collaborator | ☐ Leader |
☐ Health Advocate | ☒ Scholar | ☒ Professional |
LEARNING OBJECTIVES
- To briefly review the prevalence, etiologies and classification of focal segmental glomerulosclerosis.
- To explore mechanisms explaining the occurrence of this disease.
- To discuss the benefits and limitations of usage of genetic testing in the presence of this disease, for adult patients.
- To recommend useful therapeutic strategies to treat this disease, and debate their benefits and limitations.
- To propose an investigation and therapeutic plan useful in the process of kidney graft, for patients suffering from end-stage kidney failure related to focal segmental glomerulosclerosis.
CONFERENCE 5
“MANAGEMENT OF HYPONATREMIA: MYTHS AND REALITIES”
SPEAKER
Dr. Biff F. Palmer, MD
TARGETED CANMEDS SKILLS: | ☒ Medical Expert | ☐ Communicator | ☐ Collaborator | ☒ Leader |
☒ Health Advocate | ☒ Scholar | ☐ Professional |
LEARNING OBJECTIVES
Using clinical cases
- To briefly review the regulation of body tonicity and the mechanisms explaining the occurrence of hyponatremia.
- To define hyponatremia, its classification and discuss its etiologies.
- To integrate in daily clinical practice an algorithm of investigation and approaches of hyponatremia.
- To explore strategies to correct hyponatremia in different clinical situations, and to prevent complications related to its occurrence or to its overcorrection.
- To propose helpful clinical tools to healthcare professionals in this context.
CONFERENCE 6
“FLUID MANAGEMENT IN THE INTENSIVE CARE UNIT: TOO MUCH, TOO LITTLE, OR JUST ENOUGH?” (Lecture in French)
SPEAKER
Dr. William Beaubien-Souligny, MD, PhD
TARGETED CANMEDS SKILLS: | ☒ Medical Expert | ☐ Communicator | ☒ Collaborator | ☒ Leader |
☒ Health Advocate | ☒ Scholar | ☐ Professional |
LEARNING OBJECTIVES
- To briefly review the consequences of hypovolemia and hypervolemia for patients staying in intensive care units.
- To explore techniques, tools, biomarkers to assess adequately fluid needs and body fluid status of these patients, such as
- ultrasound
- pulse pressure variation
- oxygen saturation
- bioimpedance
- some biomarkers
- other useful tools
- To discuss the impact of usage of different types of available fluids on outcomes of patients staying in intensive care unit.
- To propose an algorithm based on useful tools and techniques to better manage these patients in the future.